MPS Pharmaa Ltd
Incorporated in 1997, MPS Pharmaa Ltd manufactures and sells pharmaceutical
products[1]
- Market Cap ₹ 3.36 Cr.
- Current Price ₹ 1.76
- High / Low ₹ 4.33 / 1.76
- Stock P/E
- Book Value ₹ 0.33
- Dividend Yield 0.00 %
- ROCE -9.79 %
- ROE -59.0 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.26 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 35.9%
- Company has a low return on equity of -38.6% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | -0.00 | -0.00 | 0.03 | -0.00 | -0.00 | -0.00 | 0.00 | |
| 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.75 | |
| Operating Profit | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.75 |
| OPM % | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| 0.01 | -0.00 | -0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 | |
| Interest | 1.20 | 1.08 | 0.08 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -0.87 |
| Tax % | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | |
| 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -0.89 | |
| EPS in Rs | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.48 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -17% |
| 5 Years: | % |
| 3 Years: | -3% |
| 1 Year: | -57% |
| Return on Equity | |
|---|---|
| 10 Years: | -24% |
| 5 Years: | -44% |
| 3 Years: | -39% |
| Last Year: | -59% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 5.05 | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -18.47 |
| 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.51 | |
| 6.52 | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.84 | |
| Total Liabilities | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
| 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.74 | |
| CWIP | -0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.65 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 2.06 | |
| Total Assets | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.62 | 2.16 | 1.25 | 0.37 | -0.34 | 0.61 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 | -0.57 | |
| -6.39 | -0.44 | -0.05 | 0.63 | 0.30 | -0.22 | 0.46 | 1.54 | 0.46 | -0.10 | 0.12 | 0.38 | |
| 1.72 | -1.75 | -1.19 | -0.98 | -0.00 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 | 0.18 | |
| Net Cash Flow | -0.05 | -0.03 | 0.01 | 0.02 | -0.04 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.00 | -0.00 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | |||||
| Inventory Days | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | ||||
| Days Payable | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | ||||
| Cash Conversion Cycle | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | |||||
| Working Capital Days | 99.72 | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | |||||
| ROCE % | 8.18% | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 And Amendment Thereof
19 Nov - Company paid Rs.2,360 BSE fine for late FY2024-25 annual report; paid 19 Nov 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - PFA Newspaper publication for publication of unaudited financial results as on 30.09.2025
-
Results As On 30.09.2025
14 Nov - Approved standalone unaudited financial results and limited review for quarter/half-year ended 30 September 2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Standalone Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September, 2025 As Required U/R 33 Of The SEBI (LODR) Regulations, 2015.
14 Nov - Board approved standalone unaudited results for quarter/half year ended 30 Sep 2025; limited review and RPT attached.
-
Board Meeting Intimation for Notice Of Board Meeting To Consider The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2025
4 Nov - Board meeting 14 Nov 2025 to approve un-audited results for quarter/half ended 30 Sep 2025; trading closed till 16 Nov.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) MPSPL (Formerly Advik Laboratories
Ltd) is in the business of manufacturing, marketing, trading, and export of Pharma Products.
b) The company has its manufacturing facility at Sohna.
c) It has various independent contract
/third-party manufacturers based across
the country